Stabilized formulations containing Anti-CD20 x Anti-CD3 bispecific antibodies
MYPI2025004341A0Undetermined Publication Date: 2021-06-10REGENERON PHARMACEUTICALS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MYPI2025004341
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-09
- Filing Date
- 2020-12-09
- Publication Date
- 2021-06-10
Abstract
The present invention provides stable liquid pharmaceutical formulations comprising a human bispecific antibody that specifically binds to human CD20 and human CD3. In certain embodiments, the formulations contain, in addition to the bispecific antibody, a buffer, a surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
Need to check novelty before this filing date? Find Prior Art
